Pyrrolobenzothiazepinones and pyrrolobenzoxazepinones: Novel and specific non-nucleoside HIV-1 reverse transcriptase inhibitors with antiviral activity

Journal of Medicinal Chemistry

Volumn 39, Issue 14, 1996, Pages 2672-2680

  Campiani, Giuseppe ^a   Nacci, Vito ^a   Fiorini, Isabella ^a   De Filippis, Maria P ^a   Garofalo, Antonio ^a   Greco, Giovanni ^b   Novellino, Ettore ^b   Altamura, Sergio ^c   Di Renzo, Laura ^c  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c IRBM   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6 ETHYL 6 PHENYLPYRROLO[2,1 D][1,5]BENZOXAZEPIN 7(6H) ONE; DNA DIRECTED DNA POLYMERASE ALPHA; NEVIRAPINE; OXAZEPINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; THIAZEPINE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS DNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; DRUG POTENCY; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; STRUCTURE ACTIVITY RELATION;

ANTIVIRAL AGENTS; CELL LINE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; OXAZEPINES; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZEPINES;

EID: 0030011406     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm950702c     Document Type: Article

References (54)

1. (a) Johnston, M. I.; Hoth, D. F. Present Status and Future Prospects for HIV Therapies. Science 1993, 260, 1286-1293.
2. (b) Fauci, A. S. The Human Immunodeficiency Virus: Infectivity and Mechanism of Pathogenesis. Science 1988, 239, 617-623.
3. (a) De Clercq, E. Chemotherapeutic Approaches to the Treatment of the Acquired Immune Deficiency Syndrome (AIDS). J. Med. Chem. 1986, 29, 1561-1568 and references cited therein.
4. (a) Price, R. W.; Brew, B.; Sidtis, J.; Rosenblum, M.; Scheck, A. C.; Cleary, P. The Brain in AIDS: Central Nervous System HIV-1 Infection and AIDS Dementia Complex. Science 1988, 239, 586-592.
5. (b) Pizzo, P. A.; Pediatric AIDS: Problems within Patients. J. Infect. Dis. 1990, 161, 316-325.
6. (c) Resnick, L.; diMarzo-Veronese, F.; Schupbach, J.; Tourtellotte, W.W.; Ho, D. D.; Muller, F.; Shapshank, P.; Vogt, M.; Groopman, J. E.; Markham, P. D.; Gallo, R. C. Intra-Blood-Brain-Barrier Synthesis of HTLV-III-Specific IgG in Patients with Neurologic Symptoms Associated with AIDS or AIDS-Related Complex. N. Engl. J. Med. 1985, 313, 1498-1507.
7. (d) Yarchoan, R.; Brouwers, P.; Spitzer, A. R.; Grafman, J.; Safai, B.; Perno, C. F.; Larson, S.; Berg, G.; Fischl, M. A.; Wichman, A.; Thomas, R. U.; Brunetti, A.; Schmidt, P. J.; Myers, C. E.; Broder, S. Response of Human Immunodeficiency-Virus-Associated Neurological Desease to 3′-Azido-3′-deoxythymidine. Lancet 1987, 132-137.
8. (e) McArthur, J. C.; Johnson, R. T. Primary Infections with Human Immuno-deficiency Virus. In AIDS and the Nervous System; Rosenblum, M. L., Levy, R. M., Bredesen, D. E., Eds.; Raven Press: New York, 1988; p 183.
9. (a) Powell, K. L.; Darby, G. HIV Reverse Transcriptase as a Target for Antiviral Drugs. In Design of Anti-AIDS Drugs; DeClercq, E., Ed.; Elsevier: New York, 1990; pp 123-140.
10. (b) Goff, S. P. Retroviral Reverse Transcriptase: Synthesis, Structure, and Function. J. AIDS 1990, 3, 817-831.
11. Mitsuya, H.; Broder, S. Strategies for Antiviral Therapy in AIDS. Nature 1987, 325, 773-778.
12. Young, S. D. Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. Perspect. Drug Disc. Des. 1993, 1, 181-192.
13. Cretton, E. M.; Xie, M.-Y.; Bevan, R. J.; Goudgaon, N. M.; Schinazi, R. F.; Sommadossi, J.-P. Catabolism of 3′-Azido-3′-deoxythymidine in Hepatocytes and Liver Microsomes with Evidence of Formation of 3′-Ammo-3′-deoxythymidine, a Highly Toxic Catabolite for Human Bone Marrow Cells. Mol. Pharmacol. 1991, 39, 258-266.
14. Terasaki, T.; Pardridge, W. M. Restricted Transport of 3′-Azido-3′-deoxythymidine and Dideoxynucleosides Through the Blood-Brain Barrier. J. Infect. Dis. 1988, 158, 630-632.
15. Kumar, R.; Wang, L.; Wiebe, L. I.; Knaus, E. E. Synthesis and Antiviral (HIV-1, HBV) Activities of 5-Halo-6-methoxy(or azido)-5,6-dihydro-3′-fluoro-3′-deoxythymidine Diastereomers. Potential Prodrugs to 3′-Fluoro-3′-deoxythymidine. J. Med. Chem. 1994, 37, 3554-3560.
16. Richman, D. D. Resistance of Clinical Isolates of Human Immunodeficiency Virus to Antiretroviral Agents. Antimicrob. Agents Chemother. 1993, 37, 1207-1221.
17. (a) Hargrave, K. D.; Proudfoot, J. R.; Grozinger, K. G.; Cullen, E.; Kapadia, S. R.; Patel, U. R.; Fuchs, V. U.; Mauldin, S. C.; Vitous, J.; Behnke, M. L.; Klunder, J. M.; Pal, K.; Skiles, J. W.; McNeil, D. W.; Rose, J. M.; Chow, G. C.; Skoog, M. T.; Wu, J. C.; Schmidt, G.; Engel, W. W.; Eberlein, W. G.; Saboe, T. D.; Campbell, S. J.; Rosenthal, A. S.; Adams, J. Novel Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. 1. Tricyclic Pyridobenzo- and Dipyridodiazepinones. J. Med. Chem. 1991, 34, 2231-2241 and references cited therein.
18. (b) Cohen, K. A.; Hopkins, J.; Ingraham, R. H.; Pargellis, G.; Wu, J. C.; Palladino, D. E. H.; Kinkade, P.; Warren, T. C.; Rogers, S.; Adams, J.; Farina, P. R.; Grob, P. M. Characterization of the Binding Site of Nevirapine (BI-RG-587), a Non-Nucleoside Inhibitor of Human Immunodeficiency Virus Type-1 Reverse Transcriptase. J. Biol. Chem. 1991, 266, 14670-14674.
19. (c) Klunder, J. M.; Hargrave, K. D.; West, M.; Cullen, E.; Pal, K.; Behnke, M. L.; Kapadia, S. R.; McNeil, D. W.; Wu, J. C.; Chow, G. C.; Adams, J. Novel Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. 2. Tricyclic Pyridobenzoxazepinones and Dibenzoxazepinones. J. Med. Chem. 1992, 35, 1887-1897.
20. (a) Pauwels, R.; Andries, K.; Desmyter, J.; Schols, D.; Kukla, M. J.; Breslin, H. J.; Raeymaeckers, A.; Van Gelder, J.; Woestenborghs, R.; Heykants, J.; Schellekens, K.; Janssen, M. A. C.; De Clercq, E.; Janssen, P. A. J. Potent and Selective Inhibition of HIV-1 Replication In Vitro by a Novel Series of TIBO Derivatives. Nature 1990, 343, 470-474.
21. (b) Breslin, H. J.; Kukla, M. J.; Ludovici, D. W.; Mohrbacher, R.; Ho, W.; Miranda, M.; Rodgers, J. D.; Hitchens, T. K.; Leo, G.; Gauthier, D. A.; Ho, C. Y.; Scott, M. K.; De Clercq, E.; Pauwels, R.; Andries, K.; Janssen, M. A. C.; Janssen, P. A. J. Synthesis and Anti-HIV-1 Activity of 4,5,6,7-Tetrahydro-5-methylimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one (TIBO) Derivatives. J. Med. Chem. 1995, 38, 771-793.
22. Goldman, M. E.; Nunberg, J. H.; O'Brien, J. A.; Quintero, J. C.; Schleif, W. A.; Freund, K. F.; Gaul, S. L.; Saari, W. S.: Wai, J. S.; Hoffman, J. M.; Anderson, P. S.; Hupe, D. J.; Emini, E. A.; Stern, A. M. Pyridone Derivatives; Specific Human Immunodeficiency Virus Type-1 Reverse Transcriptase Inhibitors with Antiviral Activity. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 6863-6867.
23. (a) Sardana, V. V.; Emini, E. A.; Gotlib, L.; Graham, D. J.; Lineberger, J. A.; Long, W. J.; Schlabach A. J.; Wolfang, J. A.; Condra, J. H. Functional Analysis of HIV-1 Reverse Transcriptase Amino Acids Involved in Resistance to Multiple Non-Nucleoside Inhibitors. J. Biol. Chem. 1992, 267, 17526-17530.
24. (b) Nunberg, J. H.; William, A. S.; Boots, E. J.; O'Brien, J. A.; Quintero, J. C.; Hoffman, J. M.; Emini, E. A.; Goldman, M. E. Viral Resistance to Human Immunodeficiency Virus Type 1-Specific Pyridinone Reverse Transcriptase Inhibitors. J. Virol. 1991, 65, 4887-4892.
25. (c) De Clercq, E. Resistance to Reverse Transcriptase Inhibitors. Biochem. Pharmacol. 1994, 47, 155-169.
26. (d) Tantillo, C.; Ding, J.; Jacobo-Molina, A.; Nanni, R. G.; Boyer, P. L.; Hughes, S. H.; Pauwels, R.; Andries, K.; Janssen, P. A. J.; Arnold, E. Locations of Anti-AIDS Drug Binding Sites and Resistance Mutations in the Three-Dimensional Structure of HIV-1 Reverse Transcriptase. J. Mol. Biol. 1994, 243, 369-387.
27. (a) Fiorini, I.; Nacci, V.; Ciani, S. M.; Garofalo, A.; Campiani, G.; Savini, L.; Novellino, E.; Greco, G.; Bernasconi, P.; Mennini, T. Novel Ligands Specific for Mithocondrial Benzodiazepine Receptors: 6-Arylpyrrolo[2,1-d][1,5]benzothiazepine Derivatives. Synthesis, Structure-Activity Relationships, and Molecular Modeling Studies. J. Med. Chem. 1994, 37, 1427-1438 and references cited therein.
28. (b) Ethyl 2-naphthyl-α-bromoacetate has been already prepared. See: (a) Hoch, J.; Choisy, J. M. Action of Sodamide on α-Bromoarylacetates. Compt. Rend. 1959, 248, 3314-3316. (b) Salageanu, N.; Sileanu, I. Action of Some Chemical Substances on the Growth of the Roots of Beans. Analele univ., C. I. Parhon Bucuresti, Ser. stiint. nat. 1956, 135-141. (c) De Luca, C.; Inesi, A.; Rampazzo, L. J. Chem. Soc., Perkin Trans. 2 1985, 209-212.
29. (b) Ethyl 2-naphthyl-α-bromoacetate has been already prepared. See: (a) Hoch, J.; Choisy, J. M. Action of Sodamide on α-Bromoarylacetates. Compt. Rend. 1959, 248, 3314-3316. (b) Salageanu, N.; Sileanu, I. Action of Some Chemical Substances on the Growth of the Roots of Beans. Analele univ., C. I. Parhon Bucuresti, Ser. stiint. nat. 1956, 135-141. (c) De Luca, C.; Inesi, A.; Rampazzo, L. J. Chem. Soc., Perkin Trans. 2 1985, 209-212.
30. (b) Ethyl 2-naphthyl-α-bromoacetate has been already prepared. See: (a) Hoch, J.; Choisy, J. M. Action of Sodamide on α-Bromoarylacetates. Compt. Rend. 1959, 248, 3314-3316. (b) Salageanu, N.; Sileanu, I. Action of Some Chemical Substances on the Growth of the Roots of Beans. Analele univ., C. I. Parhon Bucuresti, Ser. stiint. nat. 1956, 135-141. (c) De Luca, C.; Inesi, A.; Rampazzo, L. J. Chem. Soc., Perkin Trans. 2 1985, 209-212.
31. Artico, M.; Porretta, G. C.; De Martino, G. Synthesis of 4H-Pyrrolo[2,1-c][1,4]benzoxazine. J. Heterocycl. Chem. 1971, 8, 283-287.
32. Schäfer, W.; Friebe, W.-G.; Leinert, H.; Mertens, A.; Poll, T.; von der Saal, W.; Zilch, H.; Nuber, B.; Zeigler, M. L. Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase: Molecular Modeling and X-ray Structure Investigation. J. Med. Chem. 1993, 36, 726-732.
33. Kolhstaedt, L. A.; Wang, J.; Friedman, J. M.; Rice, P. A.; Steitz, T. A. Crystal Structure at 3.5 A Resolution of HIV-1 Reverse Transcriptase Complexed with an Inhibitor. Science 1992, 256, 1783-1790.
34. Smerdon, A. J.; Jager, J.; Wang, J.; Kohlstaedt, L. A.; Chirino, A. J.; Friedman, J. M.; Rice, P. A.; Steitz, T. A. Structure of the Binding Site for Non-nucleoside Inhibitors of the Reverse Transcriptase of Human Immunodeficiency Virus Type 1. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 3911-3915.
35. Jacobo-Molina A.; Ding, J.; Nanni, R. G.; Clark, A. D., Jr.; Lu, X.; Tantillo, C.; Williams, R. L.; Kamer, G.; Ferris, A. L.; Clark, P.; Hizi, A.; Hughes, S. H.; Arnold, E. Crystal Structure of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Complexed with Double-Stranded DNA at 3.0 Å Resolution Shows Bent DNA. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 6320-6324.
36. Ren, J. S.; Esnout, R.; Garman, E.; Somers, D.; Ross, C.; Kirby, I.; Keeling, J.; Darby, G.; Jones, Y.; Stuart, D.; Stammer, D. High Resolution Structure of HIV-1 RT: Insights from Four RT-Inhibitor Complexes. Nat. Struct. Biol. 1995, 2, 293-302.
37. Esnouf, R.; Ren, J. S.; Ross, C.; Jones, Y.; Stammers, D.; Stuart, D. Nat. Struct. Biol. Mechanism of Inhibition of HIV-1 Reverse Transcriptase by Non-Nucleoside Inhibitors. Nat. Struct. Biol. 1995, 2, 303-308.
38. Rodgers, D. W.; Gamblin, S. J.; Harris, B. A.; Ray, S.; Culp, J. S.; Hellmig, B.; Woolf, D. J.; Debouck, C.; Harrison, S. C. The Structure of Unliganded Reverse Transcriptase from the Human Immunodeficiency Virus Type 1. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 1222-1226.
39. Ding, J.; Das, K.; Tantillo, C.; Zhang, W.; Clark, A. D., Jr.; Jessen, S.; Lu, X.; Hsiou, Y.; Jacobo-Molina, A.; Andries, K.; Pauwels, R.; Moereels, H.; Koymans, L.; Janssen, P. A. J.; Smith, R. H., Jr.; Kroeger Koepke, M.; Michejda, C. J.; Hughes, S. H.; Arnold, E. Structure of HIV-1 Reverse Transcriptase in a Complex with the Non-nucleoside Inhibitor α-APA R 95845 at 2.8 Å Resolution. Structure 1995, 3, 365-379.
40. Ding, J.; Das, K.; Moereels, H.; Koymans, L.; Andries, K.; Janssen, P. A. J.; Hughes, S. H.; Arnold, E. Structure of HIV-1 RT/TIBO R 86183 Complex Reveals Similarity in the Binding of Diverse Non-Nucleoside Inhibitors. Nat. Struct. Biol. 1995, 2, 407-415.
41. Ren, J.; Eusnof, R.; Hopkins, A.; Ross, C.; Jones, Y.; Stammers, D.; Stuart, D. The Structure of HIV-1 Reverse Transcriptase Complexed with 9-Chloro-TIBO: Lessons for Inhibitor Design. Structure 1995, 3, 915-926.
42. Clark, M.; Cramer, R. D. III; Van Opdembosh, N. Validation of the General Purpose Tripos 5.2 Force Field. J. Comput. Chem. 1989, 10, 982-1012.
43. Gasteiger, J.; Marsili, M. Iterative Partial Equalization of Orbital Electronegativity. Tetrahedron 1980, 36, 3219-3228.
44. Purcel, V. P.; Singer, J. A. A Brief Review and Table of Semiempirical Parameters Used in the Huckel Molecular Orbital Method. J. Chem. Eng. Data 1967, 12, 235-246.
45. Pauwels, R.; Andries, K.; Debyser, Z.; Van Daele, P.; Schols, D.; Stoffels, P.; De Vreese, K.; Woestenborghs, R.; Vandamme, A.-M.; Janssen, C. G. M.; Anne, J.; Cauwenbergh, G.; Desmyter, J.; Heykants, J.; Janssen, M. A. C.; De Clercq, E.; Janssen, P. A. Potent and Highly Selective HIV-1 Inhibition by a New Series of α-Anilino Phenyl Acetamide (α-APA) Derivatives Targeted at HIV-1 Reverse Transcriptase. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 1711-1715.
46. Miyasaka, T.; Tanaka, H.; Baba, M.; Hayakawa, H.; Walker, R. T.; Balzirini, J.; De Clercq, E. A Novel Lead for Specific Anti-HIV-1 Agents: 1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)-thymine. J. Med. Chem. 1989, 32, 2507-2509.
47. 50=0.084μM (ref 10), 0.175 μM (ref 14), and 0.43 μM (ref 17).
48. Weislow, O. W.; Kiser, R.; Fine, B.; Bader, J.; Shoemaker, R.; Boyd, M. R. New Soluble-formazan Assay for HIV-1 Cytopathic Effects: Application of High-flux Screening of Synthetic and Natural Products for AIDS-antiviral Activity. J. Natl. Cancer Inst. 1989, 81, 577-586.
49. Debyser, Z.; Pauwels, R.; Andries, K.; Desmyter, J.; Kukla, M.; Janssen, P.A. J.; De Clercq, E. An Antiviral Target on Reverse Transcriptase of Human Immunodeficiency Virus Type I Revealed by Tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione Derivatives. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 1451-1455.
50. HT Biotechnology LTD directions.
51. (a) Hirschman, S. Z.; Gerber, M.; Garfinkel, E. Differential Activation of Hepatitis B DNA Polymerase by Detergents and Salts. J. Med. Virol. 1978, 2, 61-76.
52. (b) Meisel, H.; Reimer, K.; Janta-Lipinski, M. V.; Barwolff, D.; Matthes, E. Inhibition of Hepatitis B Virus DNA Polymerase by 3′-Fluorothymidine Triphosphate and Other Modified Nucleoside Triphosphate Analogs. J. Med. Virol. 1990, 30, 137-141.
53. SYBYL Molecular Modeling System (version 6.01), TRIPOS Assoc., St. Louis, MO.
54. Bernstein, F. C.; Koetzle, T. F.; Williams, G. J. B.; Meyer, E. F., Jr.; Brice, M. D.; Rodgers, J. R.; Kennard, O.; Shimanouchi, T.; Tasumi, T. The Protein Data Bank: A Computer Based Archival File for Macromolecular Structures. J. Mol. Biol. 1977, 112, 535-542.